多西他赛联合铂类治疗126例晚期非小细胞肺癌临床观察  

Clinical observation of docetaxel combined with platinum in the treatment of 126 patients with advanced non-small cell lung cancer

作　　者：韩轶群[1] 刘书盈[1] 孙继萍[1] 

机构地区：[1]济南军区总医院呼吸内科,山东济南250031

出　　处：《临床肺科杂志》2013年第2期219-221,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨多西他赛联合顺铂、卡铂及奈达铂治疗晚期非小细胞肺癌的疗效和毒副反应。方法应用多西他赛75 mg/m2联合顺铂75 mg/m2(或卡铂AUC=5,或奈达铂75 mg/m2)方案治疗126例晚期非小细胞肺癌患者。结果总有效率达48.4%,临床获益率为83.3%,其中初治与复治病例、ⅢB期与Ⅳ期病例组间的疗效差异有统计学意义(P<0.05),腺癌与鳞癌两组之间、合并使用顺铂、卡铂或奈达铂三组之间疗效差异无统计学意义(P>0.05)。主要毒副反应为骨髓抑制、恶心呕吐、腹泻及脱发。结论多西他赛联合顺铂、卡铂及奈达铂治疗晚期非小细胞肺癌疗效确切,毒副反应可耐受。Objective To explore the efficacy and side-effect of docetaxel combined with cisplatin, carboplatin or nedaplatin in the treatment of patients with non-small cell lung cancer. Methods 126 cases of advanced non-small cell lung cancer were treated with 75 mg/m2 of docetaxel combined with 75 mg/m2 of cisplatin, 75 mg/m2 of nedaplatin, or carboplatin （ AUC = 5）. Results The total ef- fective rate was 48.4% and the clinical benefit rate was 83.3%. The difference of the efficacy between the untreated and retreatment and between the stage Ⅲ B and stage Ⅳ showed statistical significance （ P 〈 0. 05 ）. The difference of the efficacy between the adenocarcinoma group and the squamous cell carcinoma group had no statistical significance, and the effect difference among the use of cisplatin, carbopla- tin and nedaplatin had no statistical significance either （ P 〉 0.05 ）. The main side effects included myelo suppression, nausea, diarrhea and hair loss. Conclusion Docetaxel combined with cisplatin, carboplatin or nedaplatin has a favorable effect and tolerable side-effect in the treatment of patients with advanced NSCLC.

关 键 词：非小细胞肺癌 多西他赛 顺铂 卡铂 奈达铂 

分 类 号：R734.2[医药卫生—肿瘤]